Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance

Q: What is the clinical evidence from this study?

Study design: Review. Population: Multiple myeloma. Intervention: Thromboprophylaxis (aspirin, low-molecular-weight heparin, or warfarin) during thalidomide therapy. Primary outcome: Venous and arterial thromboembolic events.

Q: What does this research mean for the field?

Thalidomide, especially when combined with dexamethasone or chemotherapy, significantly increases venous and arterial thromboembolic risk in multiple myeloma, necessitating routine risk-adapted thromboprophylaxis with aspirin, low-molecular-weight heparin, or warfarin. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Antonio Palumbo; Carmela Palladino

doi:10.1177/2042098612452291

June 27, 2012Therapeutic Advances in Drug SafetyOpen Access

Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance

View Full Paper

Ask AI

Bookmark

Share

Key result

Thalidomide regimens raise thromboembolism risk up to ~58%, warranting risk-stratified thromboprophylaxis.

Why the study?

How should venous and arterial thromboembolic risk be assessed and managed with thromboprophylaxis in multiple myeloma patients treated with thalidomide?

Key Points

To review the risk of venous and arterial thrombotic events associated with thalidomide in multiple myeloma and provide practical guidance on thromboprophylaxis.
Narrative clinical review evaluating evidence on thromboembolic risks associated with oral immunomodulatory drugs, particularly thalidomide, in multiple myeloma.
Synthesized literature on patient-specific, disease-related, and therapy-related risk factors for venous and arterial thrombosis.
Assessed management strategies and antithrombotic regimens, including aspirin (ASA), low-molecular-weight heparin (LMWH), and warfarin.
Thalidomide, especially when combined with chemotherapy, is associated with elevated rates of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, as well as occasional arterial thrombotic events.
Aspirin, low-molecular-weight heparin, and warfarin demonstrated similar efficacy in reducing serious thromboembolic events, though fixed low-dose warfarin showed less efficacy than low-molecular-weight heparin in elderly patients.
Routine thromboprophylaxis is recommended for multiple myeloma patients treated with thalidomide, selected according to individual risk factors and cancer treatment regimens.

Structured PICO

How should venous and arterial thromboembolic risk be assessed and managed with thromboprophylaxis in multiple myeloma patients treated with thalidomide?

P

Population

Multiple myeloma patients receiving thalidomide alone or in combination with dexamethasone, alkylating agents, or anthracyclines at elevated risk for venous and arterial thromboembolism.

I

Intervention

Thromboprophylaxis stratified by risk: low-dose aspirin (e.g., 100 mg/day) for standard-risk patients (0-1 risk factors or single-agent thalidomide), and low-molecular-weight heparin (enoxaparin 40 mg once daily or dalteparin 2500-5000 units daily) or full-dose warfarin (adjusted to target INR 2.0-3.0) for high-risk patients (≥2 risk factors or receiving thalidomide with high-dose dexamethasone, doxorubicin, or multi-agent chemotherapy) for 3-6 months.

O

Outcome

Venous thromboembolism (deep vein thrombosis and pulmonary embolism) and arterial thromboembolismhard clinical

Provides practical risk-stratified clinical guidance for selecting aspirin, LMWH, or warfarin to prevent venous and arterial thromboembolism in multiple myeloma patients receiving thalidomide-based regimens.

Limitations

Only one randomized study comparing thromboprophylaxis regimens (aspirin, warfarin, and LMWH) in myeloma patients receiving thalidomide was available at the time of review
Fixed low-dose warfarin showed less efficacy than LMWH in elderly patients and requires more extensive investigation
Newer oral anticoagulants (rivaroxaban, dabigatran) and fondaparinux require further investigation in this setting
Only one randomized controlled trial comparing aspirin, fixed low-dose warfarin, and LMWH was available at the time of the review
Fixed low-dose warfarin demonstrated lower efficacy in elderly patients compared with LMWH and requires further investigation
Role of newer anticoagulants (rivaroxaban, dabigatran, fondaparinux) in multiple myeloma patients requires further clinical investigation

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Supports risk-adapted thromboprophylaxis in thalidomide-treated myeloma; leaves open prospective validation of optimal regimens.

Abstract

Oral immunomodulatory drugs (IMiDs), namely thalidomide, lenalidomide and pomalidomide, interfere with several pathways important for disease progression. Today they play a crucial role in the treatment of multiple myeloma patients, and have considerably improved myeloma outcomes. These agents, and thalidomide in particular, are associated with higher rates of thromboembolic events, both venous and arterial. Individual risk factors for thromboembolic events include advanced age, previous history of thromboembolism, an indwelling central venous catheter, comorbid conditions (e.g. infections, diabetes, cardiac disease, obesity), current or recent immobilization, recent surgery and inherited thrombophilic abnormalities. Cancer therapy and cancer itself also increase the risk of thromboembolic events. The aim of this review is to help clinicians to define the risk of thrombotic events in patients treated with thalidomide and thus to provide practical recommendations to manage thromboprophylaxis in these patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Palumbo et al. (2012) conducted a review in Multiple myeloma. Thromboprophylaxis (aspirin, low-molecular-weight heparin, or warfarin) during thalidomide therapy was evaluated on Venous and arterial thromboembolic events.

synapsesocial.com/papers/6a92c27157a5535649a28165 https://doi.org/10.1177/2042098612452291

View Full Paper

Ask AI

Bookmark

Share

Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance

Key Points

Structured PICO

Limitations

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading